Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Ulrike Garske"'
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Background The accumulation of 177Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin receptor expression. The effect of the administered peptide mass on the resulting absorbed dose in
Externí odkaz:
https://doaj.org/article/32dff74e177348c5b1c53990a7ff6b8d
Publikováno v:
Theranostics, Vol 2, Iss 1, Pp 459-471 (2012)
Favourable outcomes of peptide receptor radiotherapy (PRRT) of neuroendocrine tumours have been reported during the last years. Still, there are uncertainties on the radionuclides to be used, the treatment planning, and the indication in patients wit
Externí odkaz:
https://doaj.org/article/0916b827f8994db8a92cb05e8c501006
Autor:
Ulrika Jahn, Mattias Sandström, Anders Sundin, Ulrike Garske-Román, Mark Lubberink, Ezgi Ilan
Publikováno v:
Neuroendocrinology. 110:662-670
Introduction: Peptide receptor radionuclide therapy (PRRT) has during the last few years been frequently used in patients with progressive, disseminating, well-differentiated neuroendocrine tumors (NETs). Objective: To study whether the absorbed dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f7bbda89813f3436f27f3f6625979db
https://doi.org/10.1159/000504001
https://doi.org/10.1159/000504001
Autor:
Ezgi Ilan, Ulrika Jahn, Mattias Sandström, Anders Sundin, Mark Lubberink, Ulrike Garske-Román
Publikováno v:
Cancers
Cancers, Vol 13, Iss 962, p 962 (2021)
Cancers, Vol 13, Iss 962, p 962 (2021)
Simple Summary Patients suffering from disseminated, progressive, neuroendocrine neoplasms with a sufficient amount of somatostatin receptors and good kidney function can be treated with radioactive hormone-like molecules to prolong their life. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2ff4355a52af12b22e7bdccf1dba2e
http://europepmc.org/articles/PMC7956792
http://europepmc.org/articles/PMC7956792
Autor:
Anders Sundin, Ulrike Garske-Román, Silvia Johansson, Mattias Sandström, Nanette Freedman, Dan Granberg
Publikováno v:
Acta Oncologica. 57:516-521
Background: Fractionated therapy with 177Lu-DOTATATE has been reported to be an effective treatment for patients with metastasized neuroendocrine tumors. To optimize the treatment, absorbed doses t...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8689b363b8a1dd4f9bd6572e801059b7
https://doi.org/10.1080/0284186x.2017.1378431
https://doi.org/10.1080/0284186x.2017.1378431
Autor:
Katarzyna, Fröss-Baron, Ulrike, Garske-Roman, Staffan, Welin, Dan, Granberg, Barbro, Eriksson, Tanweera, Khan, Mattias, Sandström, Anders, Sundin
Publikováno v:
Neuroendocrinology. 111(4)
To retrospectively analyze toxicity, progression-free survival (PFS), overall survival (OS), and their determinants in patients with advanced pancreatic neuroendocrine tumors (PanNETs), previously pretreated with chemothe-r-apy, undergoing peptide re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4e0f435bd8ac4e042228056af3beaf06
https://pubmed.ncbi.nlm.nih.gov/32097917
https://pubmed.ncbi.nlm.nih.gov/32097917
Autor:
Achyut Ram, Vyakaranam, Joakim, Crona, Olov, Norlén, Dan, Granberg, Ulrike, Garske-Román, Mattias, Sandström, Katarzyna, Fröss-Baron, Espen, Thiis-Evensen, Per, Hellman, Anders, Sundin
Publikováno v:
Cancers
Peptide receptor radiotherapy (PRRT) with 177Lu-DOTATATE has emerged as a promising therapy for neuroendocrine tumors (NETs). This retrospective cohort study aimed to assess the outcome of PRRT for 22 patients with histopathologically confirmed pheoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a8747a503be0c3dbcf77037e88d077fb
https://pubmed.ncbi.nlm.nih.gov/31261748
https://pubmed.ncbi.nlm.nih.gov/31261748
Autor:
Barbro Eriksson, Ulrike Garske-Román, Katarzyna Fröss Baron, Anders Sundin, Per Hellman, Tanweera Shaheena Khan, Silvia Johansson, Mattias Sandström, Dan Granberg, Hans Lundqvist, Staffan Welin, Lars Lundin
Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cddc1a065d5c39398ee9deab1ef1d769
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-346995
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-346995
Autor:
Ulrike, Garske-Román, Mattias, Sandström, Katarzyna, Fröss Baron, Lars, Lundin, Per, Hellman, Staffan, Welin, Silvia, Johansson, Tanweera, Khan, Hans, Lundqvist, Barbro, Eriksson, Anders, Sundin, Dan, Granberg
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7f9874a9bea27cfd97f7e974ed5e0c52
https://pubmed.ncbi.nlm.nih.gov/29497803
https://pubmed.ncbi.nlm.nih.gov/29497803
Autor:
Mattias, Sandström, Ulrike, Garske-Román, Silvia, Johansson, Dan, Granberg, Anders, Sundin, Nanette, Freedman
Publikováno v:
Acta oncologica (Stockholm, Sweden). 57(4)
Fractionated therapy withFive hundred patients with neuroendocrine tumors undergoing therapy withCross-dose to kidneys in the majority of patients were less than 2% and almost all cross-doses were less than 10%. Cross-dose exceeded 10% only in rare c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::98f7b7a6b927371f0fc46b953aa42909
https://pubmed.ncbi.nlm.nih.gov/28920501
https://pubmed.ncbi.nlm.nih.gov/28920501